No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IMUX240816C2500
- 0.10
- 0.000.00%
15min DelayClose Jul 23 15:49 ET
0.00High0.00Low
0.10Open0.10Pre Close0 Volume14 Open Interest2.50Strike Price0.00Turnover221.57%IV78.08%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.2580Delta0.3873Gamma14.60Leverage Ratio-0.0056Theta0.0002Rho3.77Eff Leverage0.0012Vega
Intraday
- 5D
- Daily
News
Immunic Stock (NASDAQ:IMUX): Exploring the Promising Phase 2 CALLIPER Trial
Express News | Piper Sandler Reiterates Overweight on Immunic, Maintains $28 Price Target
Immunic Analyst Ratings
Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer
Express News | Immunic- Jason Tardio Will Be Joining Co as Chief Operating Officer & President Effective July 12 2024
Express News | Immunic Appoints Jason Tardio as Chief Operating Officer and President
Comments
$Immunic(IMUX.US$ Immunic Announces Publication of Extended Data From Phase 2 Emphasis Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
1
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
$Immunic(IMUX.US$ Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
PR Newswire· 1 min ago
PR Newswire· 1 min ago
1
$Immunic(IMUX.US$ Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
Read more